211 related articles for article (PubMed ID: 25957699)
1. Nasal delivery of analgesic ketorolac tromethamine thermo- and ion-sensitive in situ hydrogels.
Li X; Du L; Chen X; Ge P; Wang Y; Fu Y; Sun H; Jiang Q; Jin Y
Int J Pharm; 2015 Jul; 489(1-2):252-60. PubMed ID: 25957699
[TBL] [Abstract][Full Text] [Related]
2. Enhancement in bioavailability of ketorolac tromethamine via intranasal in situ hydrogel based on poloxamer 407 and carrageenan.
Li C; Li C; Liu Z; Li Q; Yan X; Liu Y; Lu W
Int J Pharm; 2014 Oct; 474(1-2):123-33. PubMed ID: 25138250
[TBL] [Abstract][Full Text] [Related]
3. Developing Transdermal Applications of Ketorolac Tromethamine Entrapped in Stimuli Sensitive Block Copolymer Hydrogels.
Mallandrich M; Fernández-Campos F; Clares B; Halbaut L; Alonso C; Coderch L; Garduño-Ramírez ML; Andrade B; Del Pozo A; Lane ME; Calpena AC
Pharm Res; 2017 Aug; 34(8):1728-1740. PubMed ID: 28540502
[TBL] [Abstract][Full Text] [Related]
4. Poloxamer-based thermoresponsive ketorolac tromethamine in situ gel preparations: Design, characterisation, toxicity and transcorneal permeation studies.
M A Fathalla Z; Vangala A; Longman M; Khaled KA; Hussein AK; El-Garhy OH; Alany RG
Eur J Pharm Biopharm; 2017 May; 114():119-134. PubMed ID: 28126392
[TBL] [Abstract][Full Text] [Related]
5. Nasal timosaponin BII dually sensitive in situ hydrogels for the prevention of Alzheimer's disease induced by lipopolysaccharides.
Chen W; Li R; Zhu S; Ma J; Pang L; Ma B; Du L; Jin Y
Int J Pharm; 2020 Mar; 578():119115. PubMed ID: 32045690
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo studies on ocular vitamin A palmitate cationic liposomal in situ gels.
He W; Guo X; Feng M; Mao N
Int J Pharm; 2013 Dec; 458(2):305-14. PubMed ID: 24409520
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of dual action intranasal formulation intended for postoperative/cancer associated therapies.
El-Setouhy DA; Ahmed S; Badawi AA; El-Nabarawi MA; Sallam N
Eur J Pharm Sci; 2015 Aug; 76():48-56. PubMed ID: 25917526
[TBL] [Abstract][Full Text] [Related]
8. Development and in vitro evaluations of gelatin A microspheres of ketorolac tromethamine for intranasal administration.
Sankar C; Mishra B
Acta Pharm; 2003 Jun; 53(2):101-10. PubMed ID: 14764244
[TBL] [Abstract][Full Text] [Related]
9. In situ mucoadhesive-thermosensitive liposomal gel as a novel vehicle for nasal extended delivery of opiorphin.
Mura P; Mennini N; Nativi C; Richichi B
Eur J Pharm Biopharm; 2018 Jan; 122():54-61. PubMed ID: 29032194
[TBL] [Abstract][Full Text] [Related]
10. Design and evaluation of bioadhesive in-situ nasal gel of ketorolac tromethamine.
Chelladurai S; Mishra M; Mishra B
Chem Pharm Bull (Tokyo); 2008 Nov; 56(11):1596-9. PubMed ID: 18981612
[TBL] [Abstract][Full Text] [Related]
11. Formulation and evaluation of in situ gelling systems for intranasal administration of gastrodin.
Cai Z; Song X; Sun F; Yang Z; Hou S; Liu Z
AAPS PharmSciTech; 2011 Dec; 12(4):1102-9. PubMed ID: 21879392
[TBL] [Abstract][Full Text] [Related]
12. Ketorolac tromethamine formulations: an overview.
Sinha VR; Kumar RV; Singh G
Expert Opin Drug Deliv; 2009 Sep; 6(9):961-75. PubMed ID: 19663721
[TBL] [Abstract][Full Text] [Related]
13. Ketoroloac tromethamine loaded nanodispersion incorporated into thermosensitive in situ gel for prolonged ocular delivery.
Morsi N; Ghorab D; Refai H; Teba H
Int J Pharm; 2016 Jun; 506(1-2):57-67. PubMed ID: 27091293
[TBL] [Abstract][Full Text] [Related]
14. Effect of salts on gelation and drug release profiles of methylcellulose-based ophthalmic thermo-reversible in situ gels.
Bhowmik M; Bain MK; Ghosh LK; Chattopadhyay D
Pharm Dev Technol; 2011 Aug; 16(4):385-91. PubMed ID: 20429816
[TBL] [Abstract][Full Text] [Related]
15. Poloxamer/cyclodextrin/chitosan-based thermoreversible gel for intranasal delivery of fexofenadine hydrochloride.
Cho HJ; Balakrishnan P; Park EK; Song KW; Hong SS; Jang TY; Kim KS; Chung SJ; Shim CK; Kim DD
J Pharm Sci; 2011 Feb; 100(2):681-91. PubMed ID: 20803575
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary and nasal deposition of ketorolac tromethamine solution (SPRIX) following intranasal administration.
Bacon R; Newman S; Rankin L; Pitcairn G; Whiting R
Int J Pharm; 2012 Jul; 431(1-2):39-44. PubMed ID: 22525081
[TBL] [Abstract][Full Text] [Related]
17. Preparation and in vitro evaluation of controlled release hydrophilic matrix tablets of ketorolac tromethamine using factorial design.
Genç L; Jalvand E
Drug Dev Ind Pharm; 2008 Aug; 34(8):903-10. PubMed ID: 18686094
[TBL] [Abstract][Full Text] [Related]
18. Development and evaluation of nasal formulations of ketorolac.
Quadir M; Zia H; Needham TE
Drug Deliv; 2000; 7(4):223-9. PubMed ID: 11195429
[TBL] [Abstract][Full Text] [Related]
19. A novel formulation of ketorolac tromethamine for intranasal administration: preclinical safety evaluation.
Boyer KC; McDonald P; Zoetis T
Int J Toxicol; 2010; 29(5):467-78. PubMed ID: 20884857
[TBL] [Abstract][Full Text] [Related]
20. Ion activated in situ gel of gellan gum containing salbutamol sulphate for nasal administration.
Salunke SR; Patil SB
Int J Biol Macromol; 2016 Jun; 87():41-7. PubMed ID: 26899173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
